Key points are not available for this paper at this time.
IN THE SPAN OF A SEASON, A GLOBAL cadre of researchers has leveraged years of drug development into a slew of possible treatments for severe acute respiratory syndrome (SARS). Since the beginning of the SARS outbreak last spring, large drug companies have dusted off libraries of failed antivirals, famous researchers have adapted the latest anti-HIV strategy, and federal agencies have busied themselves screening thousands of existing drugs. While the World Health Organization (WHO) stopped tracking SARS cases earlier this summer, the agency warns that the disease may simply be napping. Federal agencies, led by the National Institute of Allergy and Infectious Diseases (NIAID), agree and are backing work on anti-SARS drugs.
Brian Vastag (2003) studied this question.